Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 226-237-1 | CAS number: 5332-24-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Gene mutation toxicity study was performed by Asim Kumar Debnath et al (Mutation Research, 1992) to determine the mutagenic nature of 3-Bromoquinoline (5332-24-1) using Salmonella typhimurium strains. 3-Bromoquinoline was assessed for its possible mutagenic potential. For this purpose AMES test was performed in Salmonella typhimurium strains TA 98 and TA 100. The test material was exposed at the concentration of 0, 6.7,10,33,67,100,333,667 and 1000 µg/plate in the presence and absence of S9. No mutagenic effects were observed. Only the data on TA100 with metabolic activation are reported here (Table) as the test substances tested on TA98 with and without S9 activation and on TA100without S9 activation were inactive. Therefore 3-Bromoquinoline was considered to be non mutagenic in presence and absence of S9.Hence the substance cannot be classified as gene mutant in vitro.
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Justification for type of information:
- Data is from publication.
- Qualifier:
- according to guideline
- Guideline:
- other: As mention below
- Principles of method if other than guideline:
- To evaluate the mutagenic potential of 3-Bromoquinoline in Salmonella typhimurium strains TA 98 and TA 100 by Ames test.
- GLP compliance:
- not specified
- Type of assay:
- bacterial reverse mutation assay
- Specific details on test material used for the study:
- Details on test material
- Name of test material (as cited in study report):
- Molecular formula: C9H6BrN
- Molecular weight:
- Substance type: 208.057g/mol
- Physical state: Organic
Purity;> 99% using HPLC. - Target gene:
- Histidine
- Species / strain / cell type:
- S. typhimurium, other: TA 98 and TA 100
- Details on mammalian cell type (if applicable):
- Not applicable
- Additional strain / cell type characteristics:
- not specified
- Cytokinesis block (if used):
- not specified
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 microsomal fraction
- Test concentrations with justification for top dose:
- 0,6.7,10,33,67,100,333,667 and 1000 µg/plate
- Vehicle / solvent:
- Vehicle
- Vehicle(s)/solvent(s) used: DMSO ,50µl - Untreated negative controls:
- not specified
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- other: (+ S9) 2-aminoanthracene ; TA98 and TA100 (-S9) 2-nitrofluorene ; TA98 (-S9)sodium azide;TA 100
- Details on test system and experimental conditions:
- Details on test system and conditions
METHOD OF APPLICATION: in medium; in agar (plate incorporation
DURATION
- Preincubation period: 20 min
- Exposure duration: 48 hour
NUMBER OF REPLICATIONS: Triplicates
Other: Plates not counted immediately were stored at 4°C. An automated colony counter was used for counting except when there was interference due to precipitation of test article and then manual counting was used. - Rationale for test conditions:
- Not specified
- Evaluation criteria:
- The revertants/ nmole were calculated by converting dose in Kg to nmole and taking the slope of the linear regression line of the dose-response curve. The logarithms of the slopes (revertants/ nmole) were used as activity parameters
- Statistics:
- Mean± Standard deviation was observed.
- Species / strain:
- S. typhimurium, other: TA 98 and TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- not specified
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not specified
- Positive controls validity:
- valid
- Remarks on result:
- other: No mutagenic effect were observed.
- Conclusions:
- 3-Bromoquinoline (5332-24-1) was evaluated for its mutagenic potential in Salmonella typhimurium strains TA 98 and TA 100 by Ames test. The test result was considered to be negative with and without S9.
- Executive summary:
3-Bromoquinoline was assessed for its possible mutagenic potential. For this purpose AMES test was performed in Salmonella typhimurium strains TA 98 and TA 100. The test material was exposed at the concentration of 0, 6.7,10,33,67,100,333,667 and 1000 µg/plate in the presence and absence of S9. No mutagenic effects were observed. Only the data on TA100 with metabolic activation are reported here (Table) as the test substances tested on TA98 with and without S9 activation and on TA100without S9 activation were inactive. Therefore 3-Bromoquinoline was considered to be non mutagenic in presence and absence of S9.Hence the substance cannot be classified as gene mutant in vitro.
Reference
Sr no |
|
Dose
|
Revertants/plate (mean ±standard Deviation100 (+ S9) |
1 |
Control |
|
|
|
DMSO |
50µl |
153± 3 |
2 |
Test substance name |
(µg/plate) |
|
|
3 -Bromoquinoline |
|
|
|
6.7 |
152± 17 |
|
|
10 |
160±9 |
|
|
33 |
125±7 |
|
|
67 |
157± 6 |
|
|
100 |
121±15 |
|
|
333 |
133±16 |
|
|
667 |
34±41 |
|
|
1000 |
0±0 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Genotoxicity In-vitro
Various publications were reviewed to determine the mutagenic nature of 3-Bromoquinoline (5332-24-1). The studies are as mentioned below:
Gene mutation toxicity study was performed by Asim Kumar Debnath et al (Mutation Research, 1992) to determine the mutagenic nature of 3-Bromoquinoline (5332-24-1) using Salmonella typhimurium strains. 3-Bromoquinoline was assessed for its possible mutagenic potential. For this purpose AMES test was performed in Salmonella typhimurium strains TA 98 and TA 100. The test material was exposed at the concentration of 0, 6.7,10,33,67,100,333,667 and 1000 µg/plate in the presence and absence of S9. No mutagenic effects were observed. Only the data on TA100 with metabolic activation are reported here (Table) as the test substances tested on TA98 with and without S9 activation and on TA100without S9 activation were inactive. Therefore 3-Bromoquinoline was considered to be non mutagenic in presence and absence of S9.Hence the substance cannot be classified as gene mutant in vitro.
In a study for structurally and functionally similar read across chemical, Gene mutation toxicity study was performed by Minako Nagao et al. (Mutation Research, 1977) to determine the mutagenic nature 2 Chloroquinoline (612-62-4). The read across substances share high similarity in structure and log kow .Therefore, it is acceptable to derive information on mutation from the analogue substance. In vitro genetic toxicity study was performed to determine the mutagenic nature of 2 chloroquinoline. The study was performed using Salmonella typhimurium strains TA98 and TA100 in the absence and presence of exogenous metabolic activation system. The study was carried out by using Preincubation at 37oC for 20 min. The test chemical was dissolved in DMSO and exposed at a concentration of 0, 4 or 8 µmoles /plate. 2 Chloroquinoline did not induce gene mutation in Salmonella typhimurium strain TA98 and TA100 in the presence and absence of S9 metabolic activation system and hence it does not exhibit gene mutation ability in vitro.
In a study for structurally and functionally similar read across chemical, Gene mutation toxicity study was performed by Asim Kumar Debnath et al (Mutation Research, 1992) to determine the mutagenic nature of 6-Methylquinoline (91-62-3) using Salmonella typhimurium strains. The read across substances share high similarity in structure and log kow .Therefore, it is acceptable to derive information on mutation from the analogue substance. 6-Methylquinoline was assessed for its possible mutagenic potential. For this purpose AMES test was performed in Salmonella typhimurium strains TA 98 and TA 100. The test material was exposed at the concentration of 0, 3.3,10,33,100 and 333 µg/plate in the presence and absence of S9. No mutagenic effects were observed. Only the data on TA100 with metabolic activation are reported here (Table) as the test substances tested on TA98 with and without S9 activation and on TA100without S9 activation were inactive. Therefore 6-Methylquinoline was considered to be non mutagenic in presence and absence of S9.Hence the substance cannot be classified as gene mutant in vitro.
Based on the data available for the target chemical and applying weight of evidence 3-Bromoquinoline (5332-24-1)does not exhibit gene mutation in vitro. Hence the test chemical is not likely to classify as a gene mutant in vitro.
Justification for classification or non-classification
Thus based on the above annotation and CLP criteria for the target chemical . 3-Bromoquinoline (5332-24-1)does not exhibit gene mutation in vitro. Hence the test chemical is not likely to classify as a gene mutant in vitro.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.